Elcatonin

Synthetic Calcitonin Analogue (eel Derived)Rx: PrescriptionCompound: Approved

Also known as: Carbocalcitonin, Eel calcitonin analogue, Elcitonin, SM-201

Educational Only — Not medical advice. Consult a qualified clinician before using any peptide.

Summary

Elcatonin is a synthetic analogue of eel calcitonin used primarily in Japan for the treatment of osteoporosis, hypercalcemia, and Paget's disease of bone. It has greater chemical stability and longer duration of action compared to natural calcitonin. It inhibits osteoclast-mediated bone resorption and has analgesic properties useful in managing pain associated with osteoporosis.

Mechanism of Action

Binds to calcitonin receptors on osteoclasts, inhibiting bone resorption and reducing osteoclast activity; also acts on renal tubules to increase calcium and phosphate excretion; has central analgesic effects via modulation of serotonin and beta-endorphin pathways

Routes of Administration

IntramuscularSubcutaneous

Goals & Uses

  • Osteoporosis treatmentBone MetabolismHigh
  • Hypercalcemia managementMineral MetabolismModerate
  • Paget's disease of boneBone MetabolismModerate
  • Prevention of bone loss in immobilizationBone MetabolismLow
  • Analgesic effect in bone painPain ManagementModerate

Contraindications

  • Hypersensitivity to elcatonin or calcitonin analoguesAllergyHigh
  • PregnancyPopulationModeratePotential fetal risk or insufficient safety data
  • HypocalcemiaElectrolyte DisorderHigh

Adverse Effects

  • Facial flushingCardiovascular/DermatologicCommon
  • Allergic reactionsImmunologicalRare
  • Injection site reactionsLocalCommon
  • Nausea and vomitingGastrointestinalCommon
  • HypocalcemiaMetabolicUncommon
  • DizzinessNeurologicUncommonFeeling faint, lightheaded, or unsteady

Drug Interactions

  • Loop diureticsModerate
  • BisphosphonatesLow
  • Calcium supplementsLow

Population Constraints

  • Renal impairmentOrgan ImpairmentRelative
  • Pediatric patientsAgeRelative
  • Lactating womenReproductiveRelative
  • Elderly patientsAgeRelative

Regulatory Status

  • European UnionUnapprovedNot approved by the EMA; not marketed in European Union countries
  • United StatesUnapprovedNot approved by the FDA; not marketed in the United States
  • United KingdomUnapprovedNot approved in the UK; available primarily in Japan and some Asian markets

Approved in Japan for osteoporosis and related bone conditions. Not approved by the FDA in the United States or by the EMA in Europe. Marketed primarily in Japan and some Asian countries.

Evidence & Sources

No sources recorded yet.

Browse All PeptidesBuild My Stack